Lilly and Rznomics agree $1.3 billion RNA-editing deal
Eli Lilly has entered into an agreement to develop and commercialise novel RNA-editing therapies using Rznomics’ proprietary trans-splicing ribozyme platform.
Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies.
The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss.
Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialisation.
If Lilly exercises all available options under the agreement, the total deal value could reach more than $1.3 billion, as well as separate royalties on product sales, though the upfront payment was not disclosed.
“We are thrilled to collaborate with Lilly, a global leader in pharmaceutical innovation,” said Dr Seong-Wook Lee, CEO of Rznomics. “This partnership validates our trans-splicing ribozyme platform and opens the door to treating previously intractable diseases with precision RNA therapeutics. Together with Lilly, we aim to accelerate the development of transformative therapies for patients around the world.”
This partnership marks a significant milestone for Rznomics as it seeks to expand its presence in the global biotech arena.
For Lilly, the deal aligns with its broader strategy to build a leading RNA therapeutics pipeline and address high unmet needs in hearing loss and other therapeutic areas.
Diana Spencer, Senior Digital Content Editor, DDW
